MARI International Dermatology Access Program
Facilitating Early Diagnosis of Life-Threatening Skin Cancers
112,000+
Annual invasive melanoma cases (U.S.)
8,510
Annual melanoma deaths
$8.9B
Annual skin cancer treatment cost
99% / 35%
5-year survival — early vs late stage melanoma
The Problem
Skin cancer is the most common cancer in the United States.
While early-stage disease is highly treatable, late diagnosis leads to significantly higher mortality and treatment costs.
Underserved populations often lack access to dermatological care, resulting in delayed diagnosis and poor outcomes.
The MIDAP Solution
MIDAP facilitates early diagnosis of life-threatening skin cancers through a scalable teledermatology model.
- Trained volunteers capture images of skin lesions
- Board-certified dermatologists review cases remotely
- Suspected cases are referred for timely treatment
How MIDAP Works
Image Capture
Remote Review
Diagnosis
Referral
Financial Impact
$159,808
Stage IV melanoma — over 5 years
$4,649
Stage I melanoma — total cost
Late-stage melanoma is over 22 times more expensive than early-stage disease.
Early detection can save approximately $100,000 to $155,000 per patient.
Program Impact
- Early detection increases survival from 35% to 99% in melanoma patients.
- MIDAP reduces the financial burden on healthcare systems by shifting diagnosis from late-stage to early-stage.
- The program improves patient outcomes and prevents advanced disease progression.
Target Populations
- Homeless populations
- Nursing home residents
- Frontline workers
(firefighters, construction workers, farmers) - Low-income communities
- School populations
Geographic Coverage
Our program is currently active in key U.S. regions with high melanoma burden and underserved populations.
New York
Urban underserved populations
Texas
High UV exposure regions
California
High melanoma incidence areas
Florida
High-risk population zones
Dr. Pooya Khanmohammad Beigi
Dermatologist, researcher, and founder of MARI.
Leading international initiatives focused on improving diagnostic accuracy and healthcare outcomes.
Future Vision
- Expansion beyond the United States
- Integration of AI-assisted diagnostics
- Adaptation to additional medical specialties
- International deployment
